R1 RCM Inc

R1 RCM, Inc. engages in the provision of revenue cycle management to healthcare providers. It offers end-to-end, modular revenue cycle, and physician advisory services. The company was founded by Mary Ann Tolan and J. Michael Cline in July 2003 and is headquartered in Murray, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

R1 RCM Inc (RCM) posts strong Q4 results, eyes Cloudmed growth

R1 RCM Inc (RCM) delivered robust financial performance in Q4 2022, focusing on operational excellence, technology investments, and customer engagement. Challenges include integration efforts and seasonality affecting incentive fees. The company is poised for growth with opportunities in Cloudmed expansion and AI utilization.

R1 RCM Inc (RCM) reports strong Q1 results and growth opportunities

R1 RCM Inc (RCM) delivered strong Q1 results, with a focus on operational improvements, robust Cloudmed growth, and positive financial outlook for 2023.
The company showcased resilience in stable patient self-pay trends, improving payer reimbursement timelines, and strategic capacity for onboarding new NPR, positioning itself for continued success.
Challenges include industry financial pressures, sustaining growth in legacy business, and managing operational costs effectively, requiring strategic adaptation and continuous innovation.
Opportunities lie in pipeline visibility for deals, sequential EBITDA growth, integration of Cloudmed capabilities, and strategic onboarding plans, offering avenues for expansion and profitability.

R1 RCM Inc reports robust Q2 earnings, eyes growth opportunities

R1 RCM Inc's Q2 performance was strong, with a focus on technology and operational enhancements. Challenges include revenue adjustments and workforce implications of automation. Opportunities lie in improved payer dynamics and growth through physician market focus and cross-selling.

R1 RCM Inc reports robust Q3 performance and eyes growth

R1 RCM Inc's Q3 earnings call highlighted strong financial performance, strategic priorities, and challenges in pediatric contracts and integration issues.
The company's focus on revenue optimization, leveraging technology, and partnership with Microsoft positions it well for growth opportunities within the customer base and offshoring initiatives.
While facing challenges in deal timings and debt repayment, R1 RCM Inc's emphasis on operational metrics, customer relationships, and workforce management presents avenues for continued success and industry leadership.

R1 RCM Inc reports robust Q4 earnings, eyes growth opportunities

R1 RCM Inc's Q4 2023 earnings call highlighted strong financial performance, strategic objectives for 2023, and a confident outlook for sustainable growth and shareholder value creation.
The company's emphasis on customer-centricity, AI integration, and operational efficiency underscores its strengths in revenue growth and market positioning.
While facing challenges in credit allowances and customer health, R1 RCM Inc aims to leverage opportunities in reduced costs, synergies from acquisitions, and strategic sales to drive future growth.

R1 RCM reports resilient Q1 performance post-cyberattack, eyes growth

R1 RCM showcased resilience in Q1 2024 despite the Change Healthcare cyberattack, focusing on growth strategies, operational excellence, and technology innovation.
The company faces challenges from the cyberattack impact on KPIs and vendor changes but sees opportunities in the managed care environment and customer engagement.
Overall, R1 RCM remains optimistic about transforming the industry through technology and expertise, with a strong market demand for its solutions.

R1 RCM Inc reports robust Q2 earnings amidst cyberattack challenges

R1 RCM Inc's Q2 2024 earnings call showcased strong financial performance, operational resilience in the face of cyberattacks, and a strategic focus on growth initiatives. The company faces challenges related to pending transactions and cyberattack impacts but sees opportunities in expanding its platform and leveraging technology for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against R1 RCM Corp. (“R1 RCM” or the “Company”) (NASDAQ: RCM) on behalf of R1 RCM stockholders. Our investigation concerns whether R1 RCM has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On October 16, 2023, the market analyst and investment firm Jehoshaphat Resear.

R1 RCM ALERT: Bragar Eagel & Squire, P.C. is Investigating R1 RCM Corp. on Behalf of R1 RCM Stockholders and Encourages Investors to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of R1 RCM Inc. (“RCM” or the “Company”) (NASDAQ: RCM) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your RCM investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can subm.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of R1 RCM Inc. (RCM) on Behalf of Investors

OAKLAND, Calif.--(BUSINESS WIRE)---- $RCM #RCM--Gibbs Law Group is investigating potential claims on behalf of RCM investors.

Lost Money in R1 RCM Inc.? Gibbs Law Group Investigates Potential Securities Law Violations

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of R1 RCM Inc. (“RCM” or the “Company”) (NASDAQ: RCM) investors concerning the Company's possible violations of federal securities laws. On October 16, 2023, Jehoshaphat Research published a report alleging, among other things, that RCM's “revenues and profits are grossly overstated,” that certain reported revenue growth has been “derived from inputs based on assumptions about future collections”.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of R1 RCM Inc. (RCM) on Behalf of Investors

MURRAY, Utah, Oct. 16, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced it expects to release financial results for the three months ended September 30, 2023, before market open on Thursday, November 2, 2023.

R1 RCM to Release Third Quarter 2023 Results on November 2

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of R1 RCM Inc. (“RCM” or the “Company”) (NASDAQ: RCM) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On October 16, 2023, Jehoshaphat Research published a report alleging, among other things, that RCM's “revenues and profits are grossly overstated,” that certain reported revenue growth.

The Law Offices of Frank R. Cruz Announces Investigation of R1 RCM Inc. (RCM) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of R1 RCM Inc. (NASDAQ: RCM) resulting from allegations that R1 may have issued materially misleading business information to the investing public. SO WHAT: If you purchased R1 RCM securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law.

RCM LOSS ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages R1 RCM Inc. Investors to Inquire About Securities Class Action Investigation – RCM

The heavy selling pressure might have exhausted for R1 RCM Inc. (RCM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -18.93% in 4 Weeks, Here's Why R1 RCM Inc. (RCM) Looks Ripe for a Turnaround

R1 RCM Inc. continues to offer long-term value for investors, with ongoing gains in contract balances and revenues. Recent acquisitions are starting to contribute to profitability, supporting the company's differentiated assets in revenue cycle management. The company's Q2 FY'23 numbers show strong growth in revenue and earnings, with revised guidance indicating further growth in the future.

R1 RCM: Attractively Priced, Capital Produces $0.90/Share In Earnings, Reiterate Buy

R1 RCM Inc. (NASDAQ:RCM ) Q2 2023 Earnings Conference Call August 2, 2023 8:00 AM ET Company Participants Atif Rahim - Head, Investor Relations Lee Rivas - Chief Executive Officer Jennifer Williams - Chief Financial Officer Conference Call Participants Glen Santangelo - Jefferies Sean Dodge - RBC Capital Markets Charles Rhyee - TD Cowen Sameer Patel - Evercore ISI Jailendra Singh - Truist Securities Craig Hettenbach - Morgan Stanley Hanna Lee - Bank of America Scott Schoenhaus - KeyBanc Jack Wallace - Guggenheim Securities Operator Good morning. My name is Rob, and I'll be your conference operator today.

R1 RCM Inc. (RCM) Q2 2023 Earnings Call Transcript

While the top- and bottom-line numbers for R1 RCM Inc. (RCM) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, R1 RCM Inc. (RCM) Q2 Earnings: A Look at Key Metrics

R1 RCM Inc. (RCM) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.01. This compares to earnings of $0.13 per share a year ago.

R1 RCM Inc. (RCM) Reports Break-Even Earnings for Q2

MURRAY, Utah, Aug. 02, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended June 30, 2023.

R1 RCM Reports Second Quarter 2023 Results

MURRAY, Utah, July 12, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced it expects to release financial results for the three months ended June 30, 2023, before market open on Wednesday, August 2, 2023.

R1 RCM to Release Second Quarter 2023 Results on August 2

RCM continues to increase its contract balances and net patient revenue under management. The firm is creating value for shareholders through its strategic investments. Investors are paying a higher market value in 2023 and this has all the momentum to continue.

R1 RCM: Value Proposition Is Only More Attractive Now

R1 RCM Inc. (NASDAQ:RCM ) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Atif Rahim - Head, Investor Relations Lee Rivas - Chief Executive Officer Jennifer Williams - Chief Financial Officer Conference Call Participants Charles Rhyee - TD Cowen Sean Dodge - RBC Capital Markets Michael Cherny - Bank of America Stephanie Davis - SVB Securities Jack Wallace - Guggenheim Securities Craig Hettenbach - Morgan Stanley Elizabeth Anderson - Evercore ISI Scott Schoenhaus - KeyBanc Jailendra Singh - Truist Securities Glen Santangelo - Jefferies Vikram Kesavabhotla - Baird Jeff Garro - Stephens Operator Ladies and gentlemen, thank you for standing by, and welcome to the R1 RCM First Quarter 2023 Earnings Call. I would now like to turn the call over to Atif Rahim, Head of Investor Relations.

R1 RCM, Inc. (RCM) Q1 2023 Earnings Call Transcript

R1 RCM Inc. (RCM) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.09 per share a year ago.

R1 RCM Inc. (RCM) Reports Break-Even Earnings for Q1

MURRAY, Utah, May 04, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended March 31, 2023.

R1 RCM Reports First Quarter 2023 Results

R1 RCM Inc. (RCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: R1 RCM Inc. (RCM) Q1 Earnings Expected to Decline

MURRAY, Utah, April 18, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced it expects to release financial results for the three months ended March 31, 2023, before market open on Thursday, May 4, 2023.

R1 RCM to Release First Quarter 2023 Results on May 4

The Cloudmed integration appears to be already paying dividends for R1 RCM as a growth accelerator. Projections are for 48% YoY adj. EBITDA growth in FY23.

R1 RCM: Cloudmed Already Paying Dividends, Look For Double-Digit Growth In FY23

The healthcare technology-driven solutions company posted encouraging Q4 results today.

Why R1 RCM Stock Is Surging Today

R1 RCM, Inc. (NASDAQ:RCM ) Q4 2022 Earnings Conference Call February 16, 2023 8:00 AM ET Company Participants Atif Rahim - Head, IR Lee Rivas - CEO Jennifer Williams - EVP & CFO Conference Call Participants Charles Rhyee - Cowen Michael Cherney - Bank of America Glen Santangelo - Jefferies Stephanie Davis - SVB Scott Schoenhaus - KeyBanc Jailendra Singh - Truist Sean Dodge - RBC Capital Markets Anne Samuel - J.P. Morgan Sameer Patel - Evercore ISI Craig Hettenbach - Morgan Stanley Jack Wallace - Guggenheim George Hill - Deutsche Bank Richard Close - Canaccord Operator Good morning.

R1 RCM, Inc. (RCM) Q4 2022 Earnings Call Transcript

R1 RCM Inc. (RCM) delivered earnings and revenue surprises of -200% and 2.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

R1 RCM Inc. (RCM) Reports Q4 Loss, Tops Revenue Estimates

MURRAY, Utah, Feb. 16, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months and year ended December 31, 2022.

News for R1 RCM Inc Stock (RCM)